A study conducted by Oxford University has found out that alternating doses of the AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against the coronavirus. This study, published on the Lancet pre-print server, means all possible vaccination schedules involving the Oxford-AstraZeneca and Pfizer-BioNTech vaccines could potentially be used against Covid-19. The study reveals that ‘mixed’ schedules of these vaccines induced high concentrations of antibodies against the SARS-CoV2 spike IgG protein when doses were administered four weeks apart.

"The Com-COV study has evaluated 'mix and match' combinations of the Oxford and Pfizer vaccines to see to what extent these vaccines can be used interchangeably, potentially allowing flexibility in the UK and global vaccine roll-out," said Professor Matthew Snape, Associate Professor in Paediatrics and Vaccinology at the University of Oxford, and Chief Investigator on the trial. "The results show that when given at a four-week interval both mixed schedules induce an immune response that is above the threshold set by the standard schedule of the Oxford/AstraZeneca vaccine."

Professor Snape said these results are an invaluable guide to the use of mixed dose schedules, but the interval of four weeks studied here is shorter than the eight to 12-week schedule most commonly used for the Oxford-AstraZeneca vaccine.

Study Reveals: Pfizer, Moderna Vaccines Likely Induce 'Persistent’ Immunity to COVID

Anti Covid Drug: Dr Reddy's announces commercial launch of 2-DG

Research discovers structural changes in the SARS-CoV-2 Alpha, Beta variants